{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T16:13:04Z","timestamp":1726503184348},"reference-count":0,"publisher":"MJH Life Sciences","issue":"3807","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,3]]},"abstract":"<jats:p>Neoadjuvant and adjuvant treatment in lung neuroendocrine tumors (NETs) is a field that has not been explored in-depth, with little information on the impact on disease-free survival. This case study highlights the effectiveness of neoadjuvant treatment with capecitabine plus temozolomide (CAPTEM) in a woman with well-differentiated atypical carcinoid. The patient was asymptomatic at diagnosis and was referred to the outpatient NET clinic at Sotiria Hospital in Athens, following an incidental finding on a chest x-ray. 18F-fluorodeoxyglucose (FDG) PET\/CT and 68Ga-Dotatoc PET\/CT revealed another mass in the pancreas, with avidity in both imaging studies. The patient underwent treatment for 6 months with CAPTEM with a response in the lung NET and mediastinal lymph nodes. However, the mass in the pancreas slightly increased and was removed with a central pancreatectomy. The patient continued treatment with CAPTEM for 6 more months. There was further response according to RECIST 1.1 criteria (partial response in the mediastinal lymph nodes and a 21% regression in the primary tumor size). Pathology report after lobectomy with lymph node dissection showed a pathologic complete response in the mediastinal lymph nodes. Twenty-four months after surgery, the patient remains disease-free and has a good quality of life. Although large clinical trials are needed, this case study underlines the value of preoperative chemotherapy in atypical carcinoids.<\/jats:p>","DOI":"10.46883\/2024.25921024","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T17:21:42Z","timestamp":1721323302000},"page":"264-268","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs"],"prefix":"10.46883","member":"25947","published-online":{"date-parts":[[2024,7,10]]},"container-title":["ONCOLOGY"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T17:21:44Z","timestamp":1721323304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cancernetwork.com\/view\/neoadjuvant-capecitabine-plus-temozolomide-in-atypical-lung-nets"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":0,"issue-title":["July 2024"],"journal-issue":{"issue":"3807","published-online":{"date-parts":[[2024,7,9]]},"published-print":{"date-parts":[[2024,7,3]]}},"URL":"https:\/\/doi.org\/10.46883\/2024.25921024","relation":{},"ISSN":["0890-9091"],"issn-type":[{"type":"print","value":"0890-9091"}],"subject":[],"published":{"date-parts":[[2024,7,3]]}}}